Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
about
Olanzapine for schizophreniaWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.Patient perspectives on antipsychotic treatments and their association with clinical outcomes.Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.Quality of life in schizophrenic patients.Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?Neuroleptic dysphoria: revisiting the concept 50 years later.A review of pharmacologic strategies for switching to atypical antipsychoticsThe impact of subjective well-being under neuroleptic treatment on compliance and remission.Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?Cognitive impairment associated with schizophrenia: a review of the humanistic burden.Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.Switching atypical antipsychotics: a review.Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine.Antipsychotic agents: efficacy and safety in schizophreniaQuetiapine impact on quality of life in patients with schizophrenia.Second-generation antipsychotics: looking beyond efficacy.Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review.Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study.Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics.Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophreniaSwitching patients to atypical oral antipsychotics: A retrospective audit of depot clinic attenders
P2860
Q24244031-54F55848-B00F-4D41-BB93-43978EDF22BCQ33235110-F2148C08-F8EC-4B6D-A988-3EDF5AF32FE0Q33395073-1C27F0BF-20BC-40B3-AACC-F826BCDF7041Q33738740-09CA18AB-9297-4447-A464-5DADD0CDD561Q34231565-F388F3D3-058F-4F4C-812C-0551BE19299BQ35061441-316F8C83-0705-48B3-B032-691BB4133D4BQ35236921-BD3C7CD2-F144-4486-8499-3E7EBD43465DQ35805886-36956454-8F33-4D2A-8FB4-91D718B5995DQ35805896-798D191B-0C6E-4D71-8527-F6ECF11CDF4CQ36118562-1AA8ED3D-5DCB-4320-A8A8-144DA9179C7CQ36199687-A1ABDADC-F708-48D1-B4E4-5991C112D27EQ36460707-E056DE5B-C0E3-4CDF-A669-CC23112F89E9Q36872731-45A5984D-118A-4778-B0A8-9DF0E275B2ABQ37896627-1F47710C-4148-4FC6-A593-2CA4E78FF971Q37986695-9746D48C-55D2-4A97-9BD3-85B8ED7D8A4DQ38244017-FAB2B193-630B-4BBA-A7B6-7AE867882D5DQ38777655-B44A62ED-CB1F-4505-8D0D-2B5A8F24B424Q41510821-B111FB11-A942-45B7-AB30-7CADE637AA95Q41957512-1C690C2C-A790-49C2-AA24-F39A5127806EQ44457517-ADF64004-4AFD-43BC-B052-93120F26CB7FQ44937604-966E38C0-F9D8-4F88-A1DB-8723B8058B62Q45929001-BBE10A53-531D-4013-B149-A59ACAAC55A8Q46365588-69CFF04A-1BAA-4498-98D9-81C52D1F9C94Q51915956-5FD589C7-599D-4A8D-819B-AA53C9FDB199Q52964770-2559860D-4CFE-4D78-AEDC-F3B9408B9762Q53342779-CF1B500D-F93F-43DA-BEF0-E79B34A3C5C3Q57403338-CBCE996A-3F4D-4C7A-9B14-39F293268292Q58192675-F0D18762-54C4-4841-A609-8B13BC74A9F7
P2860
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Switching from conventional to ...... rospective naturalistic study.
@en
Switching from conventional to ...... rospective naturalistic study.
@nl
type
label
Switching from conventional to ...... rospective naturalistic study.
@en
Switching from conventional to ...... rospective naturalistic study.
@nl
prefLabel
Switching from conventional to ...... rospective naturalistic study.
@en
Switching from conventional to ...... rospective naturalistic study.
@nl
P2093
P1476
Switching from conventional to ...... rospective naturalistic study.
@en
P2093
L Voruganti
Z Cernovsky
P304
P356
10.1016/S0920-9964(01)00309-7
P407
P577
2002-10-01T00:00:00Z